$PFE joint venture partner Astellas Pharma said the Japan Ministry of Health, Labour and Welfare has approved Xtandi (enzalutamide) for the treatment of metastatic hormone-sensitive prostate cancer.

The approval was based on t... https://t.co/PaaA7ZM757